Global Sterile Injectable Drugs Market 2018-2023 - Rising R&D Focus on Development of Biotechnology-Engineered Anti-Cancer Drugs

DUBLIN, Oct 1, 2018 /PRNewswire/ --

The "Global Sterile Injectable Drugs Market - Segmented by Molecule Type, Drug Class, Application and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.

The sterile injectable drugs market is expected to register a growth rate of about 10.5% over the forecast period, 2018 to 2023

The increasing number of biologics, antibody-drug conjugates, and monoclonal antibodies in development, as well as clinical trials, has led primarily led to the growth of the sterile injectable drugs. The development and manufacture of the sterile injectable are slow and often the industry deals with the shortage of these products primarily due to the complexity and capital-intensive nature of these products.

Advent of Pre-filled Syringes are Expected to Drive the Sterile Injectable Drugs Market

In the past one era of healthcare, biologics are increasingly becoming the driving forces of the pharmaceutical industry and prefilled syringes have gained increased acceptance as delivery systems for injectable drugs for the treatment of chronic diseases. Prefilled syringes are mainly sterilized via autoclaving or by ionizing radiation. The factors such as its convenient, accurate, affordable and safe with sterility have injections easier for both doctors and patients for the right dosage of the drug. There is increasing utilization of this delivery device for injectable drugs in the market which over the forecast period would grow even more as a large number of biologics manufacturers are dependent over prefilled syringes.

With rising emerging markets, there is increasing demand for patient-friendly parenteral delivery systems, therefore, prefilled syringes are one of the major drivers for sterile injectable drugs market. Other drivers include R&D focus on the development of biotech-engineered anti-cancer drugs and rising outsourcing activities across the value chain, which are expected to boost the supply of injectable drug products over the forecast period.

High Expenses Associated with Inventory Management Acts as a Major Barrier for Sterile Injectable Drugs Market

The supply chain of pharmaceutical industry deals with continuous supply and usage of a wide variety of materials with large quantities with the expected fast flow. The management of product variety and trade dependent on costs within short time windows is a big problem often faced. In the US, each year there is a high shortage of vital medicines used in the hospitals and other healthcare facilities which jeopardize patient health, comfort and safety adding to high healthcare costs.

The cost of establishing a sterile injectable plant is much higher primarily due to several stringent regulations with aseptic requirements and complex manufacturing process. For example, recently in 2018, FDA posted a warning letter for Claris (specialized in sterile injectable drugs) plant in India due to recalls related to substandard products. This hinders the collaboration of major companies and the expansion of portfolios in emerging markets. Thus, inventory management acts as a major barrier for this market.

In North America, the recent change in healthcare reforms, high adoption of drugs for oncology-related diseases in hospitals, better infrastructure and high healthcare expenditure from government boost the growth of this market, over 2018-2023.

In recent years, several hospital chains across the US, Canada, and Mexico have faced drug shortages for several chronic diseases such as cancer and pain management for which major companies such as Baxter and Pfizer looks for more collaboration opportunities with sterile injectable specialist companies. In 2018, Pfizer planned to expand manufacturing unit in Michigan especially for making sterile injectable drugs with self-contained production rooms under FDA regulations. Thus, over the forecast period, the major share of this market is expected to retained by the North America region.

Key Developments in the Sterile Injectable Drugs Market

• Berkshire Sterile Manufacturing received USD 2 million loan from Mass Development for expansion of their manufacturing unit in the US.
• Endo International PLC reached an agreement to acquire Somerset Therapeutics, LLC with USD 190 million acquisition deal.

Key Topics Covered:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis

6. Market Dynamics
6.1 Market Drivers
6.1.1 Rising R&D Focus on Development of Biotechnology-Engineered Anti-Cancer Drugs
6.1.2 Rapid Growth in the Usage of in Pre-filled Syringes for Biologic Products
6.1.3 Increased out-sourcing Activities across Value Chain Expected to Boost Supply of Injectable Products
6.2 Market Restraints
6.2.1 High Expenses Associated with Inventory Management
6.2.2 Stringent Regulatory Requirement for High-End Machinery
6.3 Market Opportunities
6.4 Key Challenges

7. Market Segmentation
7.1 By Molecule Type
7.1.1 Small Molecule
7.1.2 Large Molecule
7.2 By Drug Class
7.2.1 Blood factors
7.2.2 Cytokines
7.2.3 Peptide Hormone
7.2.4 Immunoglobulin
7.2.5 Monoclonal Antibodies (mAbs)
7.2.6 Insulin
7.2.7 Others
7.3 By Application
7.3.1 Oncology
7.3.2 Neurology
7.3.3 Cardiovascular Diseases
7.3.4 Autoimmune Diseases
7.3.5 Infectious Diseases
7.3.6 Pain
7.3.7 Others
7.4 By Geography
7.4.1 North America
7.4.1.1 US
7.4.1.2 Canada
7.4.1.3 Mexico
7.4.2 Europe
7.4.2.1 France
7.4.2.2 Germany
7.4.2.3 UK
7.4.2.4 Italy
7.4.2.5 Spain
7.4.2.6 Rest of Europe
7.4.3 Asia-Pacific
7.4.3.1 China
7.4.3.2 Japan
7.4.3.3 India
7.4.3.4 Australia
7.4.3.5 South Korea
7.4.3.6 Rest of Asia-Pacific
7.4.4 Middle East & Africa
7.4.4.1 GCC
7.4.4.2 South Africa
7.4.4.3 Rest of MEA
7.4.5 South America
7.4.5.1 Brazil
7.4.5.2 Argentina
7.4.5.3 Rest of South America

8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches

9. Key Players
9.1 Amgen
9.2 Baxter
9.3 Gilead Sciences, Inc.
9.4 GlaxoSmithKline plc
9.5 Johnson & Johnson
9.6 Merck & Co., Inc
9.7 Novartis AG
9.8 Novo Nordisk A/S
9.9 Pfizer Inc
9.10 Sanofi

For more information about this report visit https://www.researchandmarkets.com/research/lmk69n/global_sterile?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com